leuprolide acetate for depot suspension / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 138 Diseases   94 Trials   94 Trials   2090 News 
118 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
leuprolide acetate for depot suspension / Generic mfg.
ChiCTR-TRC-14005234: A Randomized Study Comparing the Side Effects and Hormonal Status of Triptorelin and Leuprorelin Following Conservative Laparoscopic Surgery for Ovarian Endometriosis in Chinese Women

Completed
4
280
 
i.m. leuprorelin ;i.m. leuprorelin
Tianjin Central Gynecology and Obstetrics Hospital; Tianjin Central Gynecology and Obstetrics Hospital, self-financing
Ovarian Endometriosis
 
 
ChiCTR-ONC-13003673: Prospective, non-intervetional, sigle centre clinical trial of leuprorelin combination with exemestane in the treatment of premature menopause metastatic breast caner

Completed
4
60
 
leuprorelin combination with exemestane
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute; Level of the institution：, Tianjin Takeda Pharmaceutical Co., Ltd.
Breast Cancer
 
 
2004-004516-22: The impact of steroid hormones on symptom provocation in patients with premenstrual dysphoric disorder.

Ongoing
4
30
Europe
leuprorelin acetate, Divigel, Progesterone, Enanton Depot, Divigel, Enanton Depot, Divigel
Uppsala University
Premenstrual Dysphoric Disorder
 
 
ChiCTR-IPR-15005971: A prospective, multicenter and randomized parallel control study on the treatment of uterine volume inducing by different Leuprorelin Acetate microspheres doses (Enantone○R) in adenomyosis.

Recruiting
4
640
 
Enantone 3.75mg ;Enantone 1.88mg ;Mirena ;oral contraceptive ;San Jie Zhen Tong capsule ;Enantone 3.75mg ;Enantone 1.88mg
Obstetrics and Gynecology Hospital of Fudan University; Obstetrics and Gynecology Hospital of Fudan University, Tianjin takeda pharmaceuticals Co. LTD
Adenomyosis
 
 
NCT02393482: Psychological Impact of Amenorrhea in Women With Endometriosis

Not yet recruiting
4
50
Europe
Estroprogestinic therapy (Etinil-estradiol/levonorgestre), Gonadotropin-releasing hormone agonist (Leuprorelin acetate), Add back therapy 1 (tibolone), Add back therapy 2 (calcium carbonate/colecalciferol)
University of Cagliari
Amenorrhea, Endometriosis, Quality of Life
12/21
06/22
NCT03963752: Clinical Trial of Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western Medicine

Completed
4
126
RoW
Ziyinxiehuo Granules Herbs, nourishing"Yin"-removing"Fire" Granules, Megestrol Acetate Tablet, Leuprorelin Acetate 3.75mg Injection
Children's Hospital of Fudan University
Idiopathic Precocious Puberty
08/22
09/22
NCT04248621: Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients

Recruiting
4
164
RoW
Leuprorelin, Leuprorelin acetate, Goserelin, Goserelin acetate, Triptorelin, Triptorelin acetate, Degarelix, Degarelix acetate, Bicalutamide, Casodex, Flutamide, Niftolide, Maximum androgen blockade, LHRN agonist and antiandrogen
Wonju Severance Christian Hospital, Eulji University Hospital
Prostatic Neoplasms
04/22
12/22
NCT03421639: Aromatase Plus GnRH Analogue Versus GnRH Analog Alone in Adenomyosis

Active, not recruiting
4
300
Europe, RoW
GnRH analog (11.25mg Leuprolide acetate), Control group, Aromatase inhibitor and GnRH analog, experimental group, Aromatase and GnRH analog (11.25mg Leuprolide acetate)
Centre for Endocrinology and Reproductive Medicine, Italy
Uterine Adenomyosis, Recurrent Implantation Failure, Menstrual Pain
09/24
09/24
2021-005005-28: Assisted reproductive technology (ART) and pregnancy outcomes in women with adenomyosis (internal endometriosis) according to stimulation protocol in relation to immunological and endometrial features: a prospective, randomized study. Esito della riproduzione assistita (ART) e della successiva gravidanza nelle donne con adenomiosi (endometriosi interna) secondo il diverso protocollo di stimolazione ovarica in relazione alle caratteristiche immunologiche ed endometriali: uno studio prospettico, randomizzato.

Not yet recruiting
4
500
Europe
Enantone, Cetrotide, Orgalutran, Visanne, Pregnyl, [-], Solution for injection, Powder and solvent for solution for injection/infusion, Tablet, Powder and solvent for solution for injection
AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA, Ministero della Salute
Women with transvaginal ultrasound (TV-US)-based diagnosis of adenomyosis and women without adenomyosis but with similar baseline reproductive risks Donne con diagnosi di adenomiosi basata sull'ecografia transvaginale (TV-US) e donne senza adenomiosi ma con rischi riproduttivi di base simili, Women with and without a diagnosis of adenomyosis with reproductive risks Donne con e senza diagnosi di adenomiosi con rischi riproduttivi, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
 
 
NCT05341115 / 2022-002471-11: A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty

Recruiting
4
80
RoW
Leuprorelin Acetate Depot 3M, Leuprolide acetate Depot 3M
Takeda, Takeda
Central Precocious Puberty
05/25
05/25
REVELUTION, NCT05320406: RElugolix VErsus LeUprolide Cardiac Trial

Active, not recruiting
4
93
US
Radiation therapy, External beam radiation therapy, Intensity modulated radiation therapy, Proton therapy, Brachytherapy, Stereotactic body radiotherapy, Leuprolide, Leuprolide acetate, Lupron, Relugolix, Orgovyx, TAK-385
Emory University, National Cancer Institute (NCI)
Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
01/25
01/26
ADENOFERT, NCT05937490: Adenomyosis and ART

Recruiting
4
500
Europe
Enantone, Dienogest 2 MG (milligram), long GnRH agonist or flexible GnRH antagonist protocol.
Azienda Ospedaliero-Universitaria di Modena, University of Modena and Reggio Emilia, Ministero della Salute, Italy
Adenomyosis
03/25
03/25
ARCH, NCT05700903: Contributions to Hypertension With Androgen Deprivation Therapy

Recruiting
4
228
US
Gonadotropin Releasing Hormone Agonists (GNRH), Leuprolide, Goserelin, Androgen receptor (AR) inhibitor, Bicalutamide, Flutamide, Enzalutamide, Placebo
University of Colorado, Denver
Androgen Deprivation Therapy, Prostate Cancer, Hypertension, Autonomic Dysfunction, Renal Disease
03/28
03/28
ChiCTR2300068147: a prospective cohort study evaluating safety and efficacy of leuprolide acetate different depot formulations in young patients with hormone receptor-positive breast cancer

Not yet recruiting
4
116
 
N/A ;N/A
Jinjiang Municipal Hospital; Jinjiang Municipal Hospital, Jinjiang Municipal Hospital
breast cancer
 
 
Uterine Leiomyoma-7: Phase III study of leuprorelin depot

Ongoing
3
0
RoW
Luphere (3 month depot) (leuprorelin depot)
Daewoong
Uterine Leiomyoma
 
 
Endometriosis & Endometrial Pain-10: Luphere Depot approved for endometriosis

Ongoing
3
0
RoW
Luphere (3 month depot) (leuprorelin depot)
Daewoong
Endometriosis & Endometrial Pain
 
 
2004-001720-21: A Phase III, multi-center, randomized, double-blind comparator study to evaluate the efficacy and safety of 50 mg and 100 mg of TAK-013 tablets administered twice daily versus 3.75mg of Leuprolide administered monthly for 24 weeks in subjects with symptomatic endometriosis.

Ongoing
3
200
Europe
Sufugolix, Leuprorelin acetate, TAK-013, Coated tablet, Powder for suspension for injection, Leuprorelin acetate
Takeda Europe R&D Centre Ltd
Endometriosis
 
 
ChiCTR-IIR-15007521: The efficacy and safety of using mifepristone in the treatment of uterine fibroids: a randomized, multiple-center controlled trial

Completed
3
300
 
Three months of daily therapy with oral mifepristone (at a dose of 10 mg) ;Three months of daily therapy with oral mifepristone (at a dose of 25 mg) ;once-monthly subcutaneous injections of enantone (at a dose of 3.75 mg)
Peking University First Hospital; Peking University First Hospital, CR Zizhu Pharmaceutical Co., Ltd
Uterine fibroids
 
 
RTOG 0534, NCT00567580: Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Active, not recruiting
3
1792
Canada, US, RoW
PBRT, Prostate bed radiotherapy, Three-Dimensional Conformal Radiation Therapy (3D-CRT), Intensity modulated RT (IMRT), PLNRT, Pelvic lymph node radiotherapy, AA, flutamide, bicalutamide, LHRH agonist, leuprolide, goserelin, buserelin, triptorelin
Radiation Therapy Oncology Group, National Cancer Institute (NCI), Cancer and Leukemia Group B, NRG Oncology
Prostate Cancer
07/18
 
NCT00430183: Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Active, not recruiting
3
788
Canada, US
docetaxel, LHRH agonist, leuprolide acetate OR, goserelin acetate, surgery
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Eastern Cooperative Oncology Group, NCIC Clinical Trials Group, Southwest Oncology Group
Prostate Cancer
10/18
10/30
NCT00936390 / 2010-020825-42: Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Active, not recruiting
3
1538
Canada, US
bicalutamide, flutamide, anti-androgen therapy, LHRH agonist (antagonist) therapy, leuprolide, goserelin, buserelin, triptorelin, degarelix, Dose-Escalated Radiation Therapy
Radiation Therapy Oncology Group, National Cancer Institute (NCI), NRG Oncology
Prostate Cancer
10/20
10/25
NCT03695237 / 2022-004131-61: A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)

Completed
3
45
US
Leuprolide Acetate (LA), Lupron Depot
AbbVie, AbbVie Inc.
Central Precocious Puberty (CPP)
05/21
11/23
NCT01546987: Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Active, not recruiting
3
239
Canada, US
GnRH agonist, LHRH analog, leuprolide, goserelin, buserelin, triptorelin, Gonadotropin-releasing hormone (GnRH) Agonist, LHRH agonist, Anti-androgen, flutamide, bicalutamide, androgen suppression, TAK-700, Radiation therapy
Radiation Therapy Oncology Group, National Cancer Institute (NCI), NRG Oncology
Prostate Cancer
11/21
06/29
BSV_LEUPR_18_05, NCT04914195: Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer

Completed
3
155
RoW
Leuprolide Acetate 3.75 MG/ML
Bharat Serums and Vaccines Limited
Advanced Prostate Adenocarcinoma
09/22
09/22
S1207, NCT01674140: Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

Active, not recruiting
3
1939
US
anastrozole, Arimidex, everolimus, Afinitor, exemestane, Aromasin, goserelin acetate, Zoladex, letrozole, Femara, leuprolide acetate, Lupron, tamoxifen citrate, nolvadex, placebo
SWOG Cancer Research Network, National Cancer Institute (NCI)
Breast Cancer
12/22
01/30
DELFINO, NCT03664895: Density Lowering Effect of "OFS Add on to TMX"( Trial)

Recruiting
3
224
RoW
Leuplin or zoladex
Seoul National University Hospital
Breast Cancer Invasive
12/24
12/24
ENDOSafe, NCT06145438: Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery

Recruiting
3
100
RoW
Dienogest, Nelandoz, Depo Medroxyprogesterone acetate, Depo Provera, Leuprolide (as Leuprolide Acetate), Tapros, Levonogestrel + etinilestradiol (30 mcg, brand name Mycrogynon), Combined oral contraceptive
Universitas Diponegoro
Endometriosis Ovary
03/24
04/24
NCT05169112: Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy

Recruiting
3
40
Canada
Lupron Depot
Ottawa Hospital Research Institute
Prostate Cancer
11/23
11/28
URONCOR 06-24, NCT05781217 / 2021-006975-41: Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624

Recruiting
3
534
Europe
triptorelin, goserelin, leuprorelin
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic, GICOR
Prostate Cancer, Salvage Radiotherapy, Biochemical Recurrence, Androgen Deprivation Therapy, Metastases-free Survival
12/23
12/32
ASPAIT, NCT02914158: Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women

Recruiting
3
680
RoW
Goserelin, Tamoxifen, Aromatase Inhibitors, Leuprolide, leuprolide acetate
First Affiliated Hospital, Sun Yat-Sen University
Breast Cancer
12/23
12/25
NCT06397703: ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer

Recruiting
3
392
US
Leuprolide, Degarelix or Relugolix, Stereotactic body radiation therapy/radiosurgery (SBRT)
NYU Langone Health
Prostate Cancer
04/28
04/28
CASPAR, NCT04455750: A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

Active, not recruiting
3
61
US
Enzalutamide, Rucaparib camsylate, Placebo, Leuprolide Acetate, Goserelin Acetate, Degarelix, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
05/24
09/26
NCT06490328: Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

Recruiting
3
154
RoW
DKF-MA102, Leuprorelin acetate
Dongkook Pharmaceutical Co., Ltd.
Advanced Prostate Cancer
05/25
05/25
GenSci093-301, NCT06449027: Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.

Not yet recruiting
3
200
RoW
T Leuprolide Injectable Emulsion, Tamoxifen Citrate Tablets, Leuprorelin Acetate Microspheres for Injection
Changchun GeneScience Pharmaceutical Co., Ltd.
Breast Cancer Subjects
11/25
03/26
PRESTO, NCT03009981: A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Active, not recruiting
3
504
US
Apalutamide, Erleada, LHRH Analogue, Degarelix (Firmagon), Leuprolide (Lupron) and Bicalutamide, Abiraterone Acetate, Zytiga, Prednisone, Deltasone
Alliance Foundation Trials, LLC., Janssen Research & Development, LLC
Prostate Cancer
07/25
01/26
DETECT V, NCT02344472 / 2014-002249-22: Detect V / CHEVENDO (Chemo vs. Endo)

Active, not recruiting
3
271
Europe
pertuzumab, Perjeta®, Trastuzumab, Herceptin®, Capecitabine, Paclitaxel, Vinorelbine, Docetaxel, Exemestane, Letrozole, Anastrozole, Fulvestrant, Ribociclib, Kisqali®, nab-Paclitaxel, eribulin, leuprorelin, goserelin
Prof. Wolfgang Janni, Roche Pharma AG, Novartis Pharmaceuticals, Eisai GmbH, Celgene Corporation
Metastatic Breast Cancer
01/25
01/25
NCT06025409: Evaluate the Efficacy and Safety of DWJ108J

Recruiting
3
79
RoW
Leuprolide Acetate 11.25 MG/ML
Daewoong Pharmaceutical Co. LTD.
Central Precocious Puberty
02/25
08/25
NCT05440383: A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia

Active, not recruiting
3
264
Japan
KLH-2109, Leuprorelin
Kissei Pharmaceutical Co., Ltd.
Uterine Fibroids (MeSH Heading: Leiomyoma)
05/25
05/25
NCT01492972: Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

Recruiting
3
192
US
Radiation, Androgen Suppression Therapy, leuprolide, goserelin, buserelin, or triptorelin
Proton Collaborative Group
Prostate Cancer
12/25
 
REPLACE-CV, NCT05605964: Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

Active, not recruiting
3
2250
US
Relugolix, ORGOVYX, TAK-385, MVT-601, RVT-601, T-1331285, Leuprolide Acetate, Leuprolide
Sumitomo Pharma Switzerland GmbH
Prostate Cancer
12/24
12/24
ADJUVANT WIDER, NCT05827081: Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Suspended
3
3100
RoW
Ribociclib, Letrozole, Ansastrozole, Goserelin, Leuprolide, Exemestane
Novartis Pharmaceuticals
Early Breast Cancer
09/29
09/30
CARLHA-2, NCT04181203: Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy

Recruiting
3
490
Europe
Apalutamide, ARN-509, Salvage radiotherapy (SRT), Luteinising Hormone Releasing Hormone agonist (LHRHa), leuprolide, goserelin, triptorelin acetate
UNICANCER, Janssen Pharmaceutica
Prostate Cancer
09/28
12/33
GUIDANCE, NCT05050084: Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score

Recruiting
3
2050
Canada, US
Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Buserelin, 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766, ICI 123215, S74-6766, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, Degarelix, FE200486, Firmagon, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Relugolix, N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, TAK 385, TAK-385, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline
NRG Oncology, National Cancer Institute (NCI)
Prostate Adenocarcinoma
04/32
04/37
PREDICT-RT, NCT04513717: Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The Trial

Recruiting
3
2478
Canada, US
Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Buserelin, 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766, ICI 123215, S74-6766, Degarelix, FE200486, Firmagon, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline
NRG Oncology, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
12/33
12/33
VA STARPORT, NCT04787744: Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

Recruiting
2/3
464
US
PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease, Goserelin, Histrelin, Leuprolide & Triptorelin, ADT + Nilutamide, Flutamide, & Bicalutamide, Degarelix & Relugolix, ADT + Docetaxel +/- prednisone, ADT + Abiraterone + Prednisone, ADT + Abiraterone + Methylprednisolone, ADT + Apalutamide, ADT + Enzalutamide, Prostate-directed Radiation for De novo oligometastatic prostate cancer
VA Office of Research and Development
Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
07/25
12/25
2014-000273-39: Trial investigating hormone injections, external beam radiotherapy and intravenous radionuclide injection in patients with advanced prostate cancer.

Ongoing
2
30
Europe
Solution for injection, Implant, , Powder and solvent for suspension for injection, Powder for suspension for injection, Xofigo 1000 kBq/mL solution for injection, Zoladex 3.6mg implant, Zoladex LA 10.8mg implant, Prostap SR DCS, Prostap 3 DCS, Decapeptyl SR 3mg, Decapeptyl SR 11.25mg
Belfast Health and Social Care Trust, Bayer PLC
Metastatic castration sensitive prostate cancer, Advanced prostate cancer, Diseases [C] - Cancer [C04]
 
 
ASN-002-IL, NCT02107391 / 2004-002708-13 / ACTRN12619001298101: Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer

Completed
2
63
RoW
Dendritic Cells DCVAC/PCa, Leuprolide acetate, Lupron, Goserelin Acetate, Zoladex
SOTIO a.s., Ascend Biopharmaceuticals Ltd
Basal Cell Carcinoma, Basal Cell Nevus Syndrome (BCNS)
12/15
06/16
2008-008722-73: ROLE OF PAROXETINE AS ADD-ON THERAPY TO GNRH AGONIST IN THE TREATMENT OF ENDOMETRIOSIS-RELATED CHRONIC PELVIC PAIN

Ongoing
2
40
Europe
ENANTONE*IM SC FL+SIR 11,25MG/, DAPAGUT*OS GTT 18,5ML20MG/20GO, ENANTONE*IM SC FL+SIR 11,25MG/, DAPAGUT*OS GTT 18,5ML20MG/20GO
AZIENDA OSPEDALIERA PISANA
Endometriosis-associated pelvic pain
 
 
2017-000154-19: A phase II randomized trial comparing alpelisib and fulvestrant versus chemotherapy as maintenance therapy in patients with PIK3CA mutated advanced breast cancer

Not yet recruiting
2
90
Europe
Alpelisib, BYL719, Tablet, Solution for injection, Implant in pre-filled syringe, Powder and solvent for solution for injection, FASLODEX, ZOLADEX, ENANTONE
UNICANCER, Novartis
PIK3CA mutated, HR+/Her2- metastatic breast cancer who do not present progressive disease after 6-8 cycles of 1st or second line chemotherapy., Breast cancer, Diseases [C] - Cancer [C04]
 
 
NCT00003915: Chemotherapy and Hormone Therapy in Treating Patients With Prostate Cancer

Active, not recruiting
2
63
US
bicalutamide, docetaxel, estramustine phosphate sodium, leuprolide acetate
University of Massachusetts, Worcester
Prostate Cancer
02/18
02/18
NCT02278185: Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

Active, not recruiting
2
19
US
Enzalutamide, MDV3100, selective androgen receptor modulator MDV3100, XTANDI, leuprolide acetate, Enantone, LEUP, Lupron, Lupron Depot, goserelin acetate, ICI-118630, ZDX, Zoladex, histrelin acetate, Supprelin, Vantas, triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, D-TRP-6-LHRH, Decapeptyl, TRIP, degarelix, ASP3550, FE200486, Firmagon
University of Colorado, Denver
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
04/19
04/25
PH002-TP-II, NCT03272477 / 2016-005157-21: Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients

Completed
2
257
Europe
Perjeta Injectable Product, Pertuzumab, Herceptin, Trastuzumab, Tamoxifen, Paclitaxel, Epirubicin, Cyclophosphamide, Anastrozole, Letrozole, Exemestane, Leuprorelin acetate, Goserelin, Leuporelin acetate, Biopsy, Surgery
Palleos Healthcare GmbH, Roche Pharma AG, WSG WOMEN´S HEALTHCARE STUDY GROUP, Cankado GmbH
Breast Neoplasms
07/20
03/24
2020-004195-17: Stereotactic hypofractionated radiotherapy with or without hormonal therapy in prostate cancer patients Radioterapia stereotassica frazionata con o senza terapia ormonale nei pazienti con tumore alla prostata

Not yet recruiting
2
146
Europe
Enantone 3,75 mg/2ml polvere, Decapeptyl, Casodex, [027066125], [026999058], [031113020], Powder and solvent for dispersion for injection, Tablet
ISTITUTI FISIOTERAPICI OSPITALIERI
Unfavorable intermediate/high risk prostae cancer patients Pazienti affetti da neoplasia prostatica a rischio intermedio sfavorevole/alto rischio, Unfavorable intermediate/high risk prostae cancer patients Pazienti affetti da neoplasia prostatica a rischio intermedio sfavorevole/alto rischio, Diseases [C] - Cancer [C04]
 
 
NCT02058706: LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

Completed
2
71
US
enzalutamide, MDV3100, selective androgen receptor modulator MDV3100, XTANDI, bicalutamide, Casodex, CDX, orchiectomy, leuprolide acetate, Enantone, LEUP, Lupron, Lupron Depot, goserelin acetate, ICI-118630, ZDX, Zoladex, laboratory biomarker analysis
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
03/21
03/21
NCT02742675: Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)

Active, not recruiting
2
200
RoW
Bicalutamide, Casodex, goserelin acetate, Zoladex, flutamide, Eulexin, leuprolide acetate, Enantone, triptorelin, Diphereline, Definitive Treatment
Fudan University
Prostate Cancer
03/21
03/23
BYLieve, NCT03056755 / 2016-004586-67: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

Checkmark Presentation of data from BYLieve trial for HR+/HER2- breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from BYLieve trial for HR+/HER2- breast cancer at SABCS 2022
Checkmark Data from BYLieve study for advanced breast cancer at ASCO 2020
May 2020 - May 2020: Data from BYLieve study for advanced breast cancer at ASCO 2020
Active, not recruiting
2
379
Europe, Canada, Japan, US, RoW
Alpelisib, BYL719, Fulvestrant, Letrozole, Goserelin, Leuprolide
Novartis Pharmaceuticals
Breast Cancer
06/21
07/25
SAVE, NCT03899077 / 2018-004365-13: Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP

Recruiting
2
202
Europe
Apalutamide, Leuprorelin Acetate 45Mg Powder for Injection Suspension Vial, Goserelin Acetate 10.8 MG Subcutaneous Implant, Triptorelin Pamoate, Degarelix acetate
Cancer Research Antwerp, Janssen Pharmaceutica
Cancer of Prostate
08/25
12/25
NCT03043807: A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

Completed
2
26
US
Leuprolide Acetate, Lupron Deport, Docetaxel, Texotere, Bicalutamide, Casodex, Radiation, Abiraterone Acetate, Zytiga
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
10/22
10/22
STARTAR, NCT03311555: A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy

Completed
2
39
US
Apalutamide, ARN-509, JNJ-56021927, Androgen deprivation, Salvage radiation therapy, Docetaxel
Andrew J. Armstrong, MD
Prostate Cancer
12/22
12/22
CARABELA, NCT04293393: Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Active, not recruiting
2
200
Europe
Doxorubicin, Caelyx, Cyclophosphamide, Genoxal, Taxane, Paclitaxel, Docetaxel, Letrozole, Femara, Abemaciclib, Verzenios, LHRH Analogue, Goserelin, Leuprolide
Spanish Breast Cancer Research Group, Eli Lilly and Company
Early Breast Cancer
06/23
02/33
NCT03541928: Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

Recruiting
2
60
US
HSV-Tk, Gene therapy, AdV-tk gene therapy, Herpes simplex virus thymidine kinase, Valacyclovir, Valtrex, Bicalutamide, Casodex, Leuprolide Acetate, Lupron, Brachytherapy, External beam radiotherapy, HDR, EBRT, Radical prostatectomy, Prostatectomy
The Methodist Hospital Research Institute
High-risk Prostate Cancer, Prostate Cancer
07/23
07/23
PLATO, NCT03900637: PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate

Active, not recruiting
2
122
RoW
Leuprorelin acetate, Leuplin, Letrozole, Lenara, Bretra, MammaPrint
Seoul National University Hospital
Breast Cancer
10/23
12/28
NeoChAI, NCT03497702: Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer

Recruiting
2
114
RoW
Doxorubicin, Cyclophosphamide, Docetaxel, Letrozole, leuprorelin
National Cancer Center, Korea
Breast Cancer, Invasive Breast Cancer
11/23
01/24
NCT01746849: Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Active, not recruiting
2
82
US
Palifermin, Lupron, peripheral blood stem cell transplantation, Total-Body Irradiation (TBI), Thiotepa, Cyclophosphamide, Degarelix
Memorial Sloan Kettering Cancer Center, Swedish Orphan Biovitrum
Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
12/24
12/24
NePtune, NCT05498272: Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations

Recruiting
2
32
US
Olaparib, Lynparza, LHRH agonist, Goserelin, Triptorelin, Leuprolide
Rana McKay, MD, AstraZeneca, University of California, San Diego
Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation, Prostatic Adenocarcinoma, High-Risk Cancer
12/25
12/26
OMPCa-ENSURE, NCT05212857: Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer

Recruiting
2
160
RoW
Leuprolide acetate, Enantone, Goserelin acetate, Zoladex, Triptorelin acetate, Diphereline, Degarelix acetate, Firmagon, Abiraterone acetate, ZYTIGA, Apalutamide, ERLEADA, Enzalutamide, Xtandi, Local treatment for primary lesion, Radiotherapy for primary lesion, Radiotherapy for metastatic lesion, Stereotactic body radiation therapy or proton and heavy ion radiation therapy
Fudan University
Prostate Cancer
02/24
09/24
STUNNIN, NCT05557604: Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer

Recruiting
2
146
Europe
Decapeptyl, Enantone
Regina Elena Cancer Institute
Prostate Cancer
02/24
02/27
ESCALATE, NCT06225284: Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients

Not yet recruiting
2
124
NA
Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg
National Taiwan University Hospital, Ministry of Health and Welfare, Debiopharm International SA
Triple Negative Breast Cancer, Premenopausal Breast Cancer
12/26
12/30
PRIME-CUT, NCT03951831: REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

Active, not recruiting
2
20
US
REGN2810, Cemiplimab, Degarelix, Firmagon, Leuprolide Acetate, Lupron, Docetaxel, Taxotere
Mark Stein, Regeneron Pharmaceuticals
Prostate Cancer Metastatic
03/24
04/28
NCT06348264: Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma

Recruiting
2
37
RoW
Rezvilutamide, Leuprolide Acetate
Peking University First Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd., Beijing Biote Pharmaceutical Co.,Ltd
Salivary Gland Neoplasm Duct
03/29
03/31
SOLAR, NCT03298087: Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

Completed
2
28
US
radical prostatectomy, stereotactic body radiotherapy, SBRT, Leuprolide, ADT, apalutamide, ARN-509, abiraterone, zytiga
VA Office of Research and Development
Newly Diagnosed Oligometastatic Prostate Cancer
03/24
03/24
DIVINE, NCT06378866: Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, Trial

Recruiting
2
120
US
Abiraterone, Abiraterone acetate, CB-7598, CB7598, Zytiga, Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography (CAT), Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, Degarelix, ASP3550, FE200486, Firmagon, Enzalutamide, ASP9785, MDV3100, Xtandi, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, Nuclear Magnetic Resonance (NMR) Imaging, NMRI, Nuclear Magnetic Resonance Imaging (NMRI), sMRI, Structural MRI (sMRI), NMR Imaging, Patient Observation, Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography (PET), Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Questionnaire Administration, Relugolix, N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, Relumina, TAK 385, TAK-385, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation (SABR), Stereotactic Ablative Body Radiation Therapy, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, AY25650, CL-118,532, CL118532, Detryptoreline
Mayo Clinic
Recurrent Castration-Sensitive Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8, Recurrent Prostate Cancer, Castration-resistant Prostate Cancer
05/29
05/29
NCT04126070: Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Active, not recruiting
2
60
US
Androgen Deprivation Therapy, Leuprolide, Lupron Depot, Goserelin acetate, Zoladex, Degarelix, Firmagon, Nivolumab, Docetaxel, Taxotere
Xiao X. Wei, MD, Bristol-Myers Squibb
Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma
12/24
06/25
NCT06528210: Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Not yet recruiting
2
32
US
Gonadotropin Releasing Hormone Agonists and Antagonists, GnRH Antagonist, Gonadotropin Releasing Hormone Inhibitor, Leuprolide, Goserelin, Triptorelin, Degarelix, Relugolix, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pembrolizumab, BCD-201, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar QL2107, QL2107, SCH 900475, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Bone Scan, Bone Scintigraphy
OHSU Knight Cancer Institute, Merck Sharp & Dohme LLC, Oregon Health and Science University
High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
06/26
06/28
NCT03007732: Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Active, not recruiting
2
23
US
Pembrolizumab, MK-3475, Keytruda, SD-101, Toll-like receptor 9, Leuprolide acetate, Intermittent androgen deprivation therapy, Abiraterone Acetate, Prednisone, Stereotactic Body Radiation Therapy, SBRT
David Oh, Prostate Cancer Foundation, Merck Sharp & Dohme LLC, TriSalus Life Sciences, Inc.
Prostatic Neoplasms
10/24
10/24
FACILE, NCT03944434 / 2018-002514-12: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer

Active, not recruiting
2
116
Europe
Ribociclib, Kisqali, Aromatase Inhibitors, non steroideal, Femara, Arimidex, LHRH agonist, Triptorelin, Leuprolide, Goserelin
Fondazione Sandro Pitigliani, Novartis
Breast Cancer
12/24
11/25
NCT00329043: Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

Active, not recruiting
2
64
US
LHRH Agonist, Lupron, Leuprolide, Sunitinib Malate, SU011248, Radical Prostatectomy
M.D. Anderson Cancer Center, Pfizer
Prostate Cancer
12/25
12/25
J2258, NCT05574712: A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer

Withdrawn
2
30
NA
Neoadjuvant treatment, leuprolide acetate, abiraterone acetate, belzutifan
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
01/25
07/26
NCT05189457: First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Active, not recruiting
2
32
US
Luteinizing Hormone Releasing Hormone, Leuprolide, Triptorelin, Goserslin, Relugolix, Degarelix, New Hormonal Agent, Abiraterone, Enzalutamide, Docetaxel, Tislelizumab, BGB-A317
H. Lee Moffitt Cancer Center and Research Institute, BeiGene
Prostate Cancer, Stage IV Prostate Cancer
07/27
07/28
NCT05765500: RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

Recruiting
2
110
US
Relugolix, Orgovyx, Leuprolide, Leuprolide Depot
Dana-Farber Cancer Institute, Prostate Cancer Foundation, Pfizer, Myovant Sciences GmbH
Prostate Cancer, Prostatic Neoplasms
07/25
01/26
NCT05924256: A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing

Recruiting
2
88
RoW
SHR-A1811, SHR 3680 + leuprolide, SHR-A1921
Fudan University
Advanced Salivary Gland Carcinoma
09/25
09/26
c15-164, NCT02772588: AASUR in High Risk Prostate Cancer

Active, not recruiting
2
64
US
ARN-509, apalutamide, JNJ-56021927, Abiraterone, Leuprolide, stereotactic, ultra-fractionated radiotherapy
Memorial Sloan Kettering Cancer Center, Janssen Pharmaceuticals, Weill Medical College of Cornell University, University of Michigan
Prostate Cancer
05/26
05/26
ADEPT, NCT04569747: A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

Recruiting
2
375
US
Pertuzumab+TRASTUZUMAB, PHESGO, ADJUVANT ENDOCRINE THERAPY, Letrozole, Anastrozole, Exemestane, Tamoxifen, Leuprolide, or other LHRH agonist (per investigator discretion)
Dana-Farber Cancer Institute, Genentech, Inc.
HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
09/26
09/30
SNARE, NCT05593497: A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

Recruiting
2
30
US
Capivasertib, abiraterone acetate
VA Office of Research and Development
High-Risk Prostate Cancer
05/27
08/27
ChiCTR2400080576: Comparing efficacy and safety of dalpiciclib in combination with neoadjuvant endocrine therapy versus neoadjuvant chemotherapy in HR-strong-positive and HER2-negative breast cancer patients: a multicenter, open, prospective Phase II study

Recruiting
2
112
 
Chemotherapy: EC*4-T*4 or AC*4-T*4 regimenDosage: A: Doxorubicin liposomes, 30-35 mg/m2, E: Epirubicin 80-100 mg/m2, C: cyclophosphamide, 600 mg/m2, T: docetaxel 80-100 mg/m2 or paclitaxel liposomes 150-175 mg/m2 or nab-paclitaxel 200-260 mg/m2; Dalpiciclib combined with endocrine therapy (plus ovarian function suppression if premenopausal) for 1 cycle in 28 days, a total of 6 cycles.Dosage: dalpiciclib 125 mg p.o. qd (21 days and 7 days off), endocrine therapy (letrozole 2.5 mg. qd or anastrozole 1.0 mg. qd or exemestane 25 mg. qd, oral, if perimenopausal, plus goserelin 3.6 mg/leuprolide 3.75 mg. Subcutaneous injection)
Sun Yat-Sen University Cancer Center; Sun Yat-Sen University Cancer Center, Jiangsu Hengrui Pharmaceuticals Co., Ltd
Breast cancer
 
 
AGAINST-PLD, NCT05478083 / 2020-005949-16: A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease

Recruiting
2
36
Europe
Leuprorelin
University Medical Center Groningen, Radboud University Medical Center
Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney
06/27
10/27
NCT05896293: Kisspeptin Administration Subcutaneously to Patients With IHH

Recruiting
2
36
US
kisspeptin 112-121, metastin 45-54, leuprolide acetate
Stephanie B. Seminara, MD
Hypogonadotropic Hypogonadism
06/27
06/27
PEER, NCT02990845: Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer

Terminated
1/2
16
RoW
Pembrolizumab/ Exemestane/ Leuprolide
National Taiwan University Hospital, Merck Sharp & Dohme LLC
Premenopausal Breast Cancer
08/22
08/22
ASCLEPIuS, NCT04194554: A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

Active, not recruiting
1/2
102
US
Niraparib, Leuprolide, Abiraterone Acetate, Stereotactic body radiotherapy (SBRT), Ultra-hypofractionated radiotherapy
University of Michigan Rogel Cancer Center, Janssen Scientific Affairs, LLC
Prostate Cancer
11/26
05/27
NCT00099086: Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer

Completed
1
20
NA
Bicalutamide, Casodex, docetaxel, Taxotere, GnRh analog, Zoladex, goserelin acetate, leuprolide acetate, Lupron, radiotherapy
Medical University of South Carolina
Prostate Cancer
01/11
12/23
NCT02023463: Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

Active, not recruiting
1
25
US
Enzalutamide, Xtandi, MDV3100, Goserelin acetate, Goserelin, Zoladex, Leuprolide acetate, Leuprorelin, Leuprolide, Radiation therapy, irradiation, radiotherapy, therapy, radiation
Sidney Kimmel Cancer Center at Thomas Jefferson University, Astellas Pharma Inc, Medivation, Inc.
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
07/17
01/40
NCT04783636: To Compare the Safety and Pharmacokinetics of PT105 With PT105R in Healthy Postmenopausal Female Volunteers

Not yet recruiting
1
40
NA
leuprorelin acetate 3.75mg, PT105
Peptron, Inc.
Prostate Cancer
07/21
07/21
ChiCTR2300069598: A Single-Center, Randomized, Open-Label, Single-Dose Comparative Study on Pharmacokinetics and Pharmacodynamics of Leuprorelin Acetate Microspheres for Injection in Healthy Subjects

Completed
1
72
 
Subjects were subcutaneously injected with the test preparation; Subjects were subcutaneously injected with the reference preparation
The Affiliated Hospital of Changchun University of Chinese Medicine; Beijing Biote Pharmaceutical Co., Ltd., Sponsor
Prostate cancer
 
 
ChiCTR2100050427: Clinical application of leuprorelin in the treatment of Kennedy's disease

Not yet recruiting
1
50
 
Leproterrine was injected subcutaneously
Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital, Self-raised
Kennedy's disease (KD)
 
 
NCT04445025: Comparison Elagolix vs Depot Leuprolide Prior to Frozen Embryo Transfers in Patients With Endometriosis

Active, not recruiting
1
30
US
Elagolix 200 MG, Leuprolide Acetate 3.75 MG/ML, Lab work
Colorado Center for Reproductive Medicine, AbbVie
Infertility, Endometriosis
09/24
12/24
NCT04760691: Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW

Recruiting
1
20
US
Truvada alone, tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), Truvada plus Leuprolide, Truvada plus Lupron, Truvada plus Estradiol 1 mg, Truvada plus low dose estrogen, Truvada plus Estradiol 6 mg, Truvada plus high dose estrogen, Estradiol 6 mg alone, Estradiol 6 mg
Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID)
Hiv, Prophylaxis, Transgender
03/25
06/25
ChiCTR2300078650: Pharmacokinetic Clinical study of Leuprorelin Acetate Microspheres for Injection in healthy subjects

Not yet recruiting
1
32
 
Leuprolide acetate microspheres for injection (trade name: inadone) ?Specification: 11.25mgManufacturer: Takeda Pharmaceutical Company LimitedProduct Lot Number: 539033; Leuprolide acetate microspheres for injection (trade name: inadone) ?Specification: 11.25mgManufacturer: Takeda Pharmaceutical Company LimitedProduct Lot Number: 508330; Leuprolide acetate microspheres for injection (trade name: inadone) ?Specification: 11.25mgManufacturer: Takeda Pharmaceutical Company LimitedProduct Lot Number: 517814; Leuprolide acetate microspheres for injection (trade name: inadone) ?Specification: 11.25mgManufacturer: Takeda Pharmaceutical Company LimitedProduct Lot Number: 539170
Wuhan Gulian Rehabilitation Hospital; Wuhan Gulian Rehabilitation Hospital, Self-funded
Endocrine diseases, carcinoma in situ of the prostate
 
 
RERPOM, ChiCTR2400080299: Rezvilutamide and Radical Prostatectomy in combination with Androgen-Deprivation Therapy in Patients with Oligometastatic Prostate Cancer (): a Randomised, Open-Label, Clinical trial

Not yet recruiting
1
100
 
Rezvilutamide 240 mg orally once daily before or after breakfast,28 days per cycle for a total of 12 treatment cycles (6 cycles before and 6 cycles following radical prostatectomy) Goserelin acetate or Leuprorelin used every cycle.Docetaxel used,21 days per cycle for a total of 6 treatment cycles; utamide 240 mg orally once daily before or after breakfast,28 days per cycle for a total of 12 treatment cycles (6 cycles before and 6 cycles following radical prostatectomy) Goserelin acetate or Leuprorelin used every cycle.
The Second Affiliated Hospital of Anhui Medical University; The Second Affiliated Hospital of Anhui Medical University, The Second Affiliated Hospital of Anhui Medical University
prostate cancer
 
 
NCT04897958: Prediction of the PRONOUNCE Prostate Cancer Trial in Healthcare Claims Data

Completed
N/A
14417
US
Degarelix, Leuprolide
Brigham and Women's Hospital
Prostate Cancer
08/21
08/21
NCT02346253: High-Dose Brachytherapy in Treating Patients With Prostate Cancer

Active, not recruiting
N/A
163
US
Internal Radiation Therapy, Brachytherapy, Internal Radiation, Internal Radiation Brachytherapy, Radiation Brachytherapy, Bicalutamide, CDX, Leuprolide Acetate, A-43818, Goserelin Acetate, ICI-118630, ZDX, Zoladex, Triptorelin Pamoate, Pamorelin, Trelstar, Degarelix, FE200486, Firmagon, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment
Stanford University, National Cancer Institute (NCI)
Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
12/21
12/26
 

Download Options